Anacaulase-bcdb (Nexobrid) — CPB 1087 | AETNA Coverage Update

Aetna modified CPB 1087 for anacaulase-bcdb (Nexobrid) enzymatic burn debridement, effective December 4, 2025. Here's what billing teams need to know before submitting claims.

Aetna, a CVS Health company, updated its coverage policy for anacaulase-bcdb (Nexobrid) under CPB 1087 in the Aetna commercial plan system. This policy governs selective enzymatic debridement for deep partial thickness and full thickness thermal burns, billed under CPT codes 0973T, 0974T, 0975T, and 0976T, with drug coverage under HCPCS J7353. The update tightens criteria around BSA limits, second-application timing, and pediatric restrictions — details that will directly drive prior authorization decisions and claim denial outcomes for burn centers and plastic surgery practices billing Aetna commercial plans.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Anacaulase-bcdb (Nexobrid) — CPB 1087
Policy Code	CPB 1087
Change Type	Modified
Effective Date	December 4, 2025
Impact Level	High
Specialties Affected	Burn surgery, plastic surgery, wound care
Key Action	Audit prior auth submissions and charge capture for CPT 0973T–0976T and HCPCS J7353 against updated BSA limits, second-application rules, and pediatric age-based dosing thresholds

---

Aetna Anacaulase-bcdb Coverage Criteria and Medical Necessity Requirements 2025

Aetna's coverage policy under CPB 1087 covers anacaulase-bcdb (Nexobrid) as medically necessary for eschar removal in adult and pediatric members with deep partial thickness and/or full thickness thermal burns. The member must have a thermal burn diagnosis — chemical and electrical burns are explicitly excluded.

The body surface area (BSA) treated per session is the central gating criterion. For adults and pediatric members age six and older, the per-session limit is 15% BSA. For pediatric members under six, the limit drops to 10% BSA. Exceed those thresholds and Aetna's medical necessity determination fails — full stop.

For adults, a second application is allowed under specific conditions. The second application must occur exactly the next calendar day after the first. That means if the first application is Tuesday, the second must happen Wednesday — not Thursday. This timing rule is strict, and it will produce claim denials if your documentation doesn't show same-treatment-course sequencing.

A second application is justified when any one of three conditions exists: the wound area exceeds 15% BSA; multiple wound areas on different body surfaces require different body positions for treatment; or the first application failed to fully remove eschar. Document which condition applies. Aetna will want to see that in the record.

The total treated area across both applications cannot exceed 20% BSA for the same treatment course. Each application is removed after four hours. Build that four-hour removal timeline into your documentation protocol — it is a clinically defined parameter Aetna will look for.

Second applications are not recommended for pediatric members. This policy does not say "less preferred" — it says not recommended. Treat that as a denial waiting to happen if you bill a second pediatric application without exceptional clinical documentation and pre-approval.

This policy covers commercial plans only. Prior authorization is required — and given the specificity of the BSA thresholds, age stratification, and second-application rules, expect Aetna to review documentation closely on every submission. If you're billing J7353 and the underlying CPT codes 0973T through 0976T without confirming prior auth is in place, you're billing blind.

Prescribing requirements matter too. This medication must be prescribed by or in consultation with a burn specialist or plastic surgeon. A general surgeon or hospitalist prescribing Nexobrid without a qualifying specialist in the loop will create a medical necessity problem before the claim is even submitted.

---

Aetna Nexobrid Exclusions and Non-Covered Indications

This is where the policy gets specific — and where your prior auth submissions will fall apart if you miss one. Aetna excludes coverage under CPB 1087 for any of the following:

The real risk here is the cardiopulmonary exclusion. Burn patients frequently have complex comorbidities. A patient with a prior STEMI or chronic heart failure who presents with a thermal burn may qualify clinically for Nexobrid — but Aetna will deny coverage if significant cardiopulmonary disease is active. Review the full problem list before submitting prior auth, not just the burn diagnosis.

The foot-burn exclusion for diabetic members is another high-risk area. Diabetic foot wounds are extremely common. If your facility treats diabetic patients with thermal foot burns and someone tries to bill J7353 for that scenario, the claim will be denied. Flag this in your charge capture workflow now.

---

Coverage Indications at a Glance

---

Aetna Nexobrid Billing Guidelines and Action Items 2025

These are direct steps your billing and prior auth teams should complete now, before the December 4, 2025 effective date passes and a claim lands in the wrong bucket.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Anacaulase-bcdb Under CPB 1087

Covered CPT Codes (When Selection Criteria Are Met)

These four Category III CPT codes are the procedure codes for Nexobrid enzymatic debridement. If your team bills enzymatic debridement for burns and hasn't already confirmed payer acceptance of 0973T–0976T on Aetna commercial claims, do that now. Category III codes carry reimbursement uncertainty across payers, and Aetna's explicit inclusion of all four in CPB 1087 is the clearest signal you have.

Covered HCPCS Code (When Selection Criteria Are Met)

Code	Type	Description Copy
J7353	HCPCS	Anacaulase-bcdb, 8.8% gel, 1 gram (not covered for circumferential burns, burn wounds where medical devices or vital structures could become exposed)

J7353 is the drug billing code for Nexobrid. The HCPCS descriptor itself includes coverage exclusions — circumferential burns and exposure-risk wounds are called out directly. That language in the descriptor reinforces what's in the policy body, and it's what your payer's claims system will read. Bill J7353 only when the underlying indication is confirmed to meet all criteria.

Key ICD-10-CM Diagnosis Codes

The policy lists 516 ICD-10-CM codes. The most billing-relevant ranges are:

The burn-specific ICD-10 codes (T codes) for thermal burn diagnoses are not listed here but are implied by the clinical criteria. Use the appropriate T-code range for the burn type and body site — and make sure no excluded body site (face, perineum, genitalia, feet in diabetic patients) is present in the diagnosis code set alongside J7353.

---